Hollis-Eden’s HE 2000 is designed to interact at what is believed to be the original source of immune dysregulation,
the hormonal balance between corticosteroids and other adrenal steroids, offering basically a hormone replacement therapy
that may lead to regulating the immune system. It has been tested for HIV in a Phase I/II clinical trial. Since a small
percentage of Hep C patients are able to clear the virus by mounting a strong cell-mediated (Th1) response, and since
HE2000 can shift patients from a Th2 immune status back to a Th1 status, the company is considering clinical studies in hepatitis C (
).
